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Abstract 
OBJECTIVE: The objective of this selective EBM review is to 
determine whether or not Flibanserin is a safe and effective 
treatment to increase sexual desire in premenopausal women with 
Hypoactive Sexual Desire Disorder. 
 
STUDY DESIGN: Review of three randomized controlled trials 
published in 2013, 2012, and 2012; selection was based on their 
relevance to the clinical question and if they contained patient 
oriented outcomes.  
DATA SOURCES: Three peer-reviewed randomized controlled trials 
comparing the use of Flibanserin to placebo in the treatment of 
Hypoactive Sexual Desire Disorder were found on PubMed.  
OUTCOME(S) MEASURED: For each trial patients were divided into 
two groups and assigned to either Flibanserin treatment or 
placebo treatment. Each trial assessed number of satisfying 
sexual events (SSE), Patient Global Impression of Improvement 
(PGI-I), and Adverse Events (AEs), events leading to the 
discontinuation of the trial. 
 
RESULTS: All three trials showed a statistically significant 
(p<.05) increase in mean change from baseline for number of 
satisfying sexual events when compared to the mean change from 
baseline of the placebo group. Thorp et al. and DeRogatis et al. 
both had PGI-I data that expressed the NNT of 6, while Katz et 
al. showed a NNT of 8. Thorp et al. reported adverse events that 
showed a NNH of 31, DeRogatis et al. reported adverse events 
that showed NNH of 12, and Katz et al. reported adverse events 
that showed NNH of 16. 
 
CONCLUSIONS: Based on all three trials, there is a statistically 
significant increase in sexual desire with the use of 
Flibanserin compared to the use of placebo in premenopausal 
women with HSDD. The analysis of PGI-I showed a moderately low 
NNT indicating that the drug, Flibanserin, was effective in 
improving the women’s condition. The analysis of AEs showed a 
moderate numbers needed to harm indicating that there are risks 
to taking Flibanserin. All serious safety concerns were 
investigated and deemed not related to the use of Flibanserin. 
Flibanserin is a relatively safe drug, and is an effective 
treatment of HSDD symptoms in premenopausal women.   
KEY WORDS: Flibanserin  
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Introduction: 
Hypoactive Sexual Desire Disorder is a sexual disorder 
characterized by low sexual desire that causes marked distress 
or interpersonal difficulty.1 Sexual dysfunction is a very common 
problem for both men and women, but treatment options for women 
are disproportionately fewer than they are for men. Historically 
female sexual dysfunction has been believed to be heavily 
psychopathologic, while male sexual dysfunction has been viewed 
as more physiologic. In addition, the topic of sex is culturally 
taboo to discuss; especially for women in America. Each of these 
factors may contribute to the disproportion of treatment options 
for women with sexual dysfunction. This paper assess three 
double-blind, randomized, controlled trials testing the efficacy 
and safety of the use of Flibanserin to increase sexual desire 
in premenopausal women with Hypoactive Sexual Desire Disorder.  
Throughout the process of the analysis of these randomized 
control trials, Flibanserin has moved on from trial phase and is 
now available to the public. Flibanserin is the first and only 
pharmacotherapy option being offered for the treatment of HSDD.   
 HSDD effects up to 14% of premenopausal women, and is the 
most commonly reported type of sexual dysfunction.2 The total 
impact that HSDD has on healthcare cost is unknown, but women 
with a diagnosis of HSDD have a total annual healthcare 
expenditure that is 16.8% higher than women without HSDD.3 This 
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is due to the fact that women with HSDD tend to have on average 
two more medical office visits per year than women without HSDD.3  
 The exact etiology of HSDD is unknown, but it is thought to 
be multifactorial. Possible contributing factors include, 
decreased testosterone or estrogen levels, psychological 
factors, and sociological factors such as relationship conflict.4  
 Prior to Flibanserin there were no pharmacotheraputics for 
the treatment of HSDD. Often patients with HSDD see a counselor 
or a sex therapist to help with psychological factors 
contributing to the disease. Other treatments consist of herbal 
remedies. The top herbal remedies are Provestra, Femestril, and 
Vigorelle.4 Even though there are multiple options available for 
the treatment of HSDD, there is no current treatment that is 
effective in all patients. For this reason there is a need for 
more treatment options of HSDD. Therefore, determining the 
safety and efficacy of Flibanserin is important.  
Objective:  
The objective of this selective EBM review is to determine 
whether or not Flibanserin is a safe and effective treatment to 
increase sexual desire in premenopausal women with Hypoactive 
Sexual Desire Disorder.  
Methods: 
Three double blind, randomized controlled trials, were 
included in this systematic review. Studies were selected based 
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on various criteria including populations studied, interventions 
used, comparisons made, and outcomes measured. In all three 
studies, the populations being measured consisted of healthy 
premenopausal women greater than or equal to the age of 18 with 
a diagnosis of HSDD. The women in the study also had to be in a 
stable, communicative, monogamous, heterosexual relationship of 
> 1 year’s duration and had to have a sexually functional 
partner. Each article measured the effects of 100mg of 
Flibanserin taken orally once daily before bedtime and compared 
it to the effects of taking a visually equivalent placebo pill 
at bedtime. Each of the articles also measured desire and 
improvement in libido by recording the following: number of 
satisfying sexual events (SSE) and Patient’s Global Impression 
of Improvement (PGI-I). Each article measured safety by 
recording the number of Adverse Events (AE).  
All three articles were researched via the PubMed database 
and were selected based on relevance to the clinical question.  
Each article was also selected on the basis that their measured 
outcomes were patient oriented evidence that matters (POEMS). 
The Key word entered in the PubMed search was “Flibanserin”.  
All three of the selected studies were peer reviewed journal 
articles written in the English language published between 2012 
and 2013.  
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The studies included in this systematic review were 
selected based on the following inclusion criteria: all were 
primary research studies (randomized controlled trials, cohort 
studies, crossover studies, etc.), all were published after 
1998, all included relevant POEMs, and all evaluated the safety 
and efficacy of Flibanserin on Hypoactive Sexual Desire Disorder 
as one of the measured outcomes. Exclusion criteria included 
women under 18 years of age, women with sexual dysfunctions 
other than HSDD; any other psychiatric disorder that could 
impact sexual function; MDD within the previous 6 months; a 
score of 14 on the Beck Depression Inventory-II; any ongoing 
serious clinical disorder; or substance abuse in the past year. 
Statistics reported included standard deviations, p-values, and 
mean change from baseline. Table 1 below shows the demographics 
and characteristics of the included studies. 
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Table 1: Demographics and Characteristics of Included Studies 
Study Type # of 
Pts 
Age Inclusion Exclusion W/D Interventio
n 
Begonia 
(2013) 
RDBPC 1090 36.5 
+/-8 
Premenopausal women 
>18 years old, with 
diagnosis of HSDD. A 
Female Sexual 
Distress 
ScaleRevised (FSDS-
R) score of at least 
15, indicating 
sexual distress, and 
a Sexual Interest 
and Desire 
Inventory-Female 
receptivity item 
rating of 0 or 1, 
indicating little or 
no receptivity to 
partner’s sexual 
approach. Women had 
to be in a stable, 
communicative, 
monogamous, 
heterosexual 
relationship of > 1 
year’s duration and 
to have a sexually 
functional partner. 
Sexual 
dysfunctions 
other than 
HSDD, arousal 
disorder, or 
orgasm 
disorder; any 
other 
psychiatric 
disorder that 
could impact 
sexual 
function; MDD 
within the 
previous 6 
months; a score 
of 14 on the 
Beck Depression 
Inventory-II; 
any ongoing 
serious 
clinical 
disorder; or 
substance abuse 
in the past 
year. 
233 Flibanserin 
100mg qhs 
Violet 
(2012) 
RDBPC 585 35.5 
+/- 7 
152 Flibanserin 
100mg qhs 
Daisy 
(2012) 
RDBPC 794 35.4 
+/- 7 
255 Flibanserin 
100mg qhs 
 
Outcomes Measured: 
All three articles measured the number of satisfying sexual 
events (SSE), Patient Global Impression of Improvement (PGI-I), 
and Adverse Events (AEs). SSE was recorded by the subjects via 
an eDiary. A sexual event was defined as sexual intercourse, 
oral sex, masturbation, or genital stimulation by a partner.1,5,6 
In order to measure sexual desire improvement each article used 
PGI-I. PGI-I consisted of a single question, “How is your 
condition today compared with when you started the study 
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medication?” Subjects answered the question on a 1-7 scale 1 
(very much improved), 4 (no change), and 7 (very much worse). 
PGI was measured at weeks 4, 8, 16, and 24.1,5,6 To determine 
safety of Flibanserin use, Adverse Events leading to the 
discontinuation of the trial was measured throughout the 
duration of the trial.  
Results: 
 Three double-blind randomized controlled trials compared 
the effects of 100 mg of Flibanserin with a visually equivalent 
placebo pill on premenopausal women with HSDD. Thorp et al. 
assigned 399 women to placebo and 396 women to the experimental 
group. Of the 399 women in the placebo group, 111 discontinued 
the trial; 43 due to adverse events and 68 due to various 
reasons such as non-compliance or being lost to follow up. Of 
the 395 women receiving Flibanserin, 144 discontinued; 62 due to 
adverse events, and the remaining to other causes.5 Katz et al. 
assigned 547 women to the placebo group and 543 women into the 
Flibanserin group. Of the 547 women in the placebo group, 99 
discontinued the trial, 20 due to adverse events and the 
remainder for various reasons. Of the 543 women in the 
Flibanserin group, 134 discontinued the trial, 53 due to adverse 
events.1 DeRogatis et al. assigned 295 women into the placebo 
group and 290 into the Flibanserin group. Of the 295 women in 
the placebo group, 61 discontinued the trial; 10 due to adverse 
Lee, Flibanserin and HSDD, 7 
 
events. Of the 290 women in the Flibanserin group 91 women 
discontinued, 33 due to adverse events.6 Graph 1, seen below, 
illustrates withdrawal numbers in all three trials. 
 
Graph 1: Subject withdrawals and completions.   
All three trials showed a statistically significant (p<.05) 
increase in mean change from baseline for number of satisfying 
sexual events when compared to the mean change from baseline of 
the placebo group. These results are illustrated in Table 2 
below.  
Table 2: Efficacy of Flibanserin in the treatment of Hyposexual 
Desire Disorder using Satisfying Sexual Events.  
Study Flibanserin 100 mg. 
Mean change from 
baseline (SD) 
Placebo Mean change 
from baseline (SD) 
P value 
Thorp et al. 1.9 (.3) 1.1(.2) <.01 
DeRogatis et al. 1.6 (.23) .8 (.2) <.01 
Katz et al.  2.5 (4.6) 1.5 (4.5) <.001 
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All three randomized control trials reported PGI-I scores 
after the 24 weeks of the trial was over. Data from these trials 
were reported as continuous data that was later converted into 
dichotomous format to evaluate efficacy of treatment. Thorp et 
al. reported PGI-Is that showed 47% of women who were taking 
Flibanserin felt an improvement in their condition while 30.3% 
of women taking placebo felt that their condition had improved; 
that results in a NNT of 6.5 DeRogatis et al. reported PGI-Is 
that showed 50% of women who were taking Flibanserin felt an 
improvement in their condition while 30.3% of women taking 
placebo felt that their condition had improved; that results in 
a NNT of 6.6 A NNT of 6 means that if 6 people were treated with 
Flibanserin, one person would benefit more than that of people 
taking placebo. Katz et al. reported PGI-Is that showed 51.8% of 
women who were taking Flibanserin felt an improvement in their 
condition while 37.7% of women taking placebo felt that their 
condition had improved; that results in a NNT of 8.1 The results 
for PGI-I are illustrated in Table 3 seen below.  
Table 3: Efficacy of Flibanserin in the treatment of Hyposexual 
Desire Disorder using PGI-I.  
Study CER EER RBI ABI NNT 
Thorp et al. .303 .500 .650 .197 6 
DeRogatis et al. .303 .470 .55 .168 6 
Katz et al.  .377 .518 .374 .141 8 
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Adverse events data from all three trials was reported as 
continuous data and was later converted into dichotomous format 
to evaluate safety of treatment. Thorp et al. reported adverse 
events in 13.4% of those taking Flibanserin and 10.1% of those 
taking placebo, resulting in a NNH of 31.5 A NNH of 31 means that 
it takes 31 people to be treated with Flibanserin before 1 
adverse event happens that wouldn’t have otherwise happened 
using the placebo. DeRogatis et al. reported adverse events in 
11.4% of those taking Flibanserin and 3.4% of those taking 
placebo, resulting in a NNH of 12.6 Katz et al. reported adverse 
events in 9.6% of those taking Flibanserin and 3.7 % of those 
taking placebo, resulting in a NNH of 16.1 The results of adverse 
events are illustrated in Table 4 seen below. The most common 
adverse effects reported in all three trials were somnolence, 
dizziness, nausea, and fatigue.1,5,6 In all three cases, the 
serious adverse events were deemed not related to the drug by 
the investigator. 
Table 4: Safety of Flibanserin in the treatment of Hyposexual 
Desire Disorder using.  
Study CER EER RRI ARI NNH 
Thorp et al. .034 .114 2.35 .08 12.5→12 
DeRogatis et al. .101 .134 .327 .033 30.3→30 
Katz et al.  .037 .096 1.59 .059 16.96 →16 
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Discussion: 
Using three double-blind RCT’s, this meta-analysis reviewed 
the safety and efficacy of Flibanserin in improving the sexual 
desire in premenopausal women ≥18 years old with HSDD. All three 
trials showed that in premenopausal women with HSDD taking 100mg 
of Flibanserin before bed was associated with a statistically 
significant increase in sexual desire expressed by SSE. The 
analysis of PGI-I showed a moderately low NNT indicating that 
the drug, Flibanserin, was effective in improving the women’s 
condition. The analysis of AEs showed a moderate numbers needed 
to harm indicating that there are risks to taking Flibanserin. 
All serious safety concerns were investigated and deemed not 
related to the use of Flibanserin.  
Conclusion: 
Based on the three studies above, it can be concluded that 
Flibanserin is effective at improving the condition and 
increasing sexual desire in women in premenopausal women with 
HSDD, but the risks and benefits must be weighed on an 
individual basis. No serious or life threatening risks have been 
identified as a result of the use of Flibanserin. Flibanserin is 
a relatively safe drug and is an effective treatment of HSDD 
symptoms in premenopausal women.  
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